RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.

Epidaza (chidamide) - Chipscreen

Rituxan (rituximab) - Roche

lenalidomide - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42124356

Cong Li; Haifeng Yu; Haiyan Yang; Jialiang Lu; Shuailing Peng; Shuiyun Han; Tao Lei; Xi Chen; Xiang Weng; Xiu Zhu; Xiyue Xu; Zhilu Chen

May 13, 2026